Oscar Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Oscar Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.70B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $9.18B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $5.86B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $3.96B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.84B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $462.80M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $488.19M | Feb 25, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.59M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $20.58M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $21.35M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $64.93M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $5.39M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $0 | Feb 24, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($443.15M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $25.43M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($270.73M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($606.28M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($572.61M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($406.83M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($261.18M) | Feb 25, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($396.36M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $57.27M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($235.62M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($589.87M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($544.48M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($402.27M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($259.39M) | Feb 25, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.05B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.76B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.43B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.26B | Feb 20, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $978.19M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($272.16M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $380.35M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($181.75M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $222.73M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($165.37M) | Feb 25, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.33B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $4.84B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $3.60B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $4.53B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.32B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $2.27B | Feb 25, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.34B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.82B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.80B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.63B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.93B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.82B | Feb 25, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $977.65M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $803.97M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $890.38M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.39B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($1.30B) | Feb 25, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.29B) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($2.85B) | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | ($2.88B) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($2.61B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($2.00B) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($1.43B) | Feb 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.77B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.53B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.87B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.56B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.10B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $826.33M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $336.64M | Feb 25, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | (14) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | (9) | Feb 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | (14) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | (9) | Feb 25, 2022 |